Successful generation of structural information for fragment-based drug discovery

Drug Discovery Today

Volumn 20, Issue 9, 2015, Pages 1104-1111

  Öster, Linda ^a   Tapani, Sofia ^a   Xue, Yafeng ^a   Käck, Helena ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; DRUG;

ARTICLE; BINDING SITE; CRYSTAL; CRYSTALLOGRAPHY; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG STRUCTURE; FRAGMENT BASED DRUG DISCOVERY; FRAGMENT CRYSTALLOGRAPHY; INFORMATION PROCESSING; CHEMISTRY; DRUG DESIGN; HUMAN; PROCEDURES; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS;

EID: 84941025550     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.04.005     Document Type: Review

References (63)

1. M. Congreve, and et al. Structural biology and drug discovery Drug Discov. Today 10 2005 895 907
2. D.F. Wyss Structure-guided applications in drug discovery Drug Discov. Today 8 2003 924 926
3. H. Jubb, and et al. Structural biology and drug discovery for protein-protein interactions Trends Pharmacol. Sci. 33 2012 241 248
4. R.E. Hubbard Structure-based drug discovery and protein targets in the CNS Neuropharmacology 60 2011 7 23
5. R.A. Norman, and et al. Structural approaches to obtain kinase selectivity Trends Pharmacol. Sci. 33 2012 273 278
6. C.W. Murray, and et al. Experiences in fragment-based drug discovery Trends Pharmacol. Sci. 33 2012 224 232
7. S.P. Andrews, and et al. Structure-based and fragment-based GPCR drug discovery ChemMedChem 9 2014 256 275
8. M. Baker Fragment-based lead discovery grows up Nat. Rev. Drug Discov. 12 2013 5
9. T. Hesterkamp, and et al. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions Curr. Top. Med. Chem. 7 2007 1582 1591
10. G.L. Card, and et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design Nat. Biotechnol. 23 2005 201 207
11. V.L. Nienaber, and et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening Nat. Biotechnol. 18 2000 1105 1108
12. T.G. Davies, and I.J. Tickle Fragment screening using X-ray crystallography Top. Curr. Chem. 317 2012 33 59
13. C. Dalvit NMR methods in fragment screening: theory and a comparison with other biophysical techniques Drug Discov. Today 14 2009 1051 1057
14. P.S. Kutchukian, and et al. Large scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologies J. Biomol. Screen. 2014 pii:1087057114565080
15. S.B. Shuker, and et al. Discovering high-affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534
16. G.E. de Kloe, and et al. Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discov. Today 14 2009 630 646
17. G. Chessari, and A.J. Woodhead From fragment to clinical candidate - a historical perspective Drug Discov. Today 14 2009 668 675
18. M. Whittaker, and et al. Fragments: past, present and future Drug Discov. Today: Technol. 7 2010 e163 e171
19. C.W. Murray, and T.L. Blundell Structural biology in fragment-based drug design Curr. Opin. Struct. Biol. 20 2010 497 507
20. G.W. Tang, and R.B. Altman Knowledge-based fragment binding prediction PLoS Comput. Biol. 2014 10.1371/journal.pcbi.1003589
21. A.R. Leach, and et al. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps J. Med. Chem. 49 2006 5851 5855
22. G. Marcou, and D. Rognan Optimizing fragment and scaffold docking by use of molecular interaction fingerprints J. Chem. Inf. Model. 47 2007 195 207
23. P.S. Stewart, and J. Mueller-Dieckmann Automation in biological crystallization Acta Crystallogr. F: Struct. Biol. Commun. 70 2014 686 696
24. A. D'Arcy, and et al. Microseed matrix screening for optimization in protein crystallization: what have we learned? Acta Crystallogr. F: Struct. Biol. Commun. 70 2014 1117 1126
25. G. Zhang, and et al. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer Prog. Lipid Res. 53 2014 108 123
26. H.C. Shen, and B.D. Hammock Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications J. Med. Chem. 55 2012 1789
27. J. Bottcher, and et al. Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology Methods Enzymol. 493 2011 61 89
28. Z.S. Derewenda Application of protein engineering to enhance crystallizability and improve crystal properties Acta Crystallogr. D: Biol. Crystallogr. 66 2010 604 615
29. M.A. Bukowska, and M.G. Grutter New concepts and aids to facilitate crystallization Curr. Opin. Struct. Biol. 23 2013 409 416
30. G. Saxty, and et al. Identification of orally bioavailable small-molecule inhibitors of hematopoietic prostaglandin D2 synthase using X-ray fragment based drug discovery Med. Chem. Commun. 5 2014 134 141
31. D.M. George, and et al. Discovery of selective and orally bioavailable protein kinase Ctheta (PKCtheta) inhibitors from a fragment hit J. Med. Chem. 1 2015 222 236
32. G.A. Gomez, and et al. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis Biochemistry 43 2004 4716 4723
33. R.A. Ward, and et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation J. Med. Chem. 55 2012 3285 3306
34. S.R. LaPlante, and et al. Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus J. Med. Chem. 57 2014 2074 2090
35. J.D. Bauman, and et al. Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening J. Med. Chem. 56 2013 2738 2746
36. J. Rouhana, and et al. Fragment-based identification of a locus in the Sec7 domain of Arno for the design of protein-protein interaction inhibitors J. Med. Chem. 56 2013 8497 8511
37. A.L. Perryman, and et al. Fragment-based screen against HIV protease Chem. Biol. Drug Des. 75 2010 257 268
38. A. Kohlmann, and et al. Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors J. Med. Chem. 56 2013 1023 1040
39. H.L. Silvestre, and et al. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery Proc. Natl. Acad. Sci. U. S. A. 110 2013 12984 12989
40. S. Surade, and et al. A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR Biochem. J. 458 2014 387 394
41. C. Dalvit, and et al. NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening Curr. Drug Discov. Technol. 3 2006 115 124
42. A. Vulpetti, and et al. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine J. Am. Chem. Soc. 131 2009 12949 12959
43. M.I. Recht, and et al. Fragment-based screening for inhibitors of PDE4A using enthalpy arrays and X-ray crystallography J. Biomol. Screen. 17 2012 469 480
44. C.W. Chung The use of biophysical methods increases success in obtaining liganded crystal structures Acta Crystallogr. D: Biol. Crystallogr. 63 2007 62 71
45. D.E. Danley Crystallization to obtain protein-ligand complexes for structure-aided drug design Acta Crystallogr. D: Biol. Crystallogr. 62 2006 569 575
46. C.J. Lusty A gentle vapor-diffusion technique for cross-linking of protein crystals for cryocrystallography J. Appl. Crystallogr. 32 1999 106 112
47. A.M. Hassell, and et al. Crystallization of protein-ligand complexes Acta Crystallogr. D: Biol. Crystallogr. 63 2007 72 79
48. T. Hesterkamp, and M. Whittaker Fragment-based activity space: smaller is better Curr. Opin. Chem. Biol. 12 2008 260 268
49. M.I. Recht, and et al. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography J. Biomol. Screen. 19 2014 497 507
50. Y. Amano, and et al. Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography Bioorg. Med. Chem. 22 2014 2427 2434
51. S.Z. Grinter, and et al. Automated large-scale file preparation, docking, and scoring: evaluation of ITScore and STScore using the 2012 Community Structure-Activity Resource benchmark J. Chem. Inf. Model. 53 2013 1905 1914
52. A.D. Favia, and et al. SERAPhiC: a benchmark for in silico fragment-based drug design J. Chem. Inf. Model. 51 2011 2882 2896
53. J.B. Dunbar Jr., and et al. CSAR data set release 2012: ligands, affinities, complexes, and docking decoys J. Chem. Inf. Model. 53 2013 1842 1852
54. L. Hu, and et al. Binding MOAD (mother of all databases) Proteins 60 2005 333 340
55. G.L. Warren, and et al. Essential considerations for using protein-ligand structures in drug discovery Drug Discov. Today 17 2012 1270 1281
56. S. Howard, and et al. Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase ACS Med. Chem. Lett. 4 2013 1208 1212
57. J.A. Christopher, and et al. Biophysical fragment screening of the beta1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design J. Med. Chem. 56 2013 3446 3455
58. G. Lolli, and R. Battistutta Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain Acta Crystallogr. D: Biol. Crystallogr. 69 2013 2161 2164
59. Y.S. Cho, and et al. Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active CDK4/6 inhibitors ACS Med. Chem. Lett. 3 2012 445 449
60. C.N. Johnson, and et al. Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase ACS Med. Chem. Lett. 1 2014 31 36
61. T. Tiefenbrunn, and et al. Crystallographic fragment-based drug discovery: use of a brominated fragment library targeting HIV protease Chem. Biol. Drug Des. 83 2014 141 148
62. J.D. Bauman, and et al. Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors ACS Chem. Biol. 8 2013 2501 2508
63. Hopkins, A.L. et al. (2014) The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105-121